Memento Medicines, a Boston-based biotech developing biologic therapies for retinal diseases, raises $93 million in Series A funding. Forbion, RA Capital Management, and Avego BioScience Capital lead the round.
Jun 2026 · FinSMEsNews article
Memento Medicines Launches with $93 Million Series A Financingglobenewswire.com/news-release/2026/06/18/3314508/0/en/memento-medicines-launches-with-93-million-series-a-financing-to-advance-tie2-agonist-and-vegf-inhibitor-bispecific-antibody-therapy-for-retinal-diseases.html
Memento Medicines launches after completing a $93 million Series A financing. The round is co-led by Forbion, RA Capital Management and Avego BioScience Capital, with participation from Sanofi Ventures and Samsara BioCapital; the company also has exclusive worldwide rights to MMT-205.
Brown Rudnick advises Memento Medicines on a global license agreement with Korean biotechnology companies MabTics and Curacle for MMT-205, a Tie2/VEGF bispecific antibody for retinal disease. The agreement is valued at $1 billion.
